Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab
Renaud Heine(Erasmus University Rotterdam), Carin A. Uyl‐de Groot(Erasmus University Rotterdam), Roelof W. F. van Leeuwen(Erasmus MC), Ron H.J. Mathijssen(Erasmus MC), Frederick W. Thielen(University Medical Center Freiburg), M Franken(Erasmus University Rotterdam)
Cited by 6
Related Papers
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
|PubMed|2001|752
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
|The Lancet Oncology|2018|419
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
|New England Journal of Medicine|2020|418
Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
|New England Journal of Medicine|2020|345
Proximal Tubular Secretion of Creatinine by Organic Cation Transporter OCT2 in Cancer Patients
|Clinical Cancer Research|2012|164